Log In
Print
BCIQ
Print
Print this Print this
 

NS-018

  Manage Alerts
Collapse Summary General Information
Company Nippon Shinyaku Co. Ltd.
DescriptionJAK2/Src inhibitor
Molecular Target Janus kinase-2 (JAK-2) ; Src
Mechanism of ActionSrc inhibitor; Janus kinase-2 (JAK-2) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationHematologic malignancies
Indication DetailsTreat hematologic malignancies; Treat myelofibrosis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today